Summary

Viscosupplementation Market Summary

The global viscosupplementation market size was estimated at USD 5.30 billion in 2024 and is projected to reach USD 9.39 billion by 2033, growing at a CAGR of 6.21% from 2025 to 2033. Viscosupplementation aims to alleviate joint pain and enhance the functional state of the knee.

The growing incidence of osteoarthritis plays a significant role in driving the demand for viscosupplementation. Osteoarthritis, a chronic degenerative joint disease, is the primary cause of enduring disability. It typically emerges after the age of 30 and can progress to a disabling condition within a decade of diagnosis. In March 2025, an article published in Scientific Reports analyzed osteoarthritis data from the Global Burden of Disease Study 2021. The study reported a sharp rise in global OA incidence from 20.9 million cases in 1990 to 46.6 million in 2021, with a notable increase in years lived with disability. It also highlighted growing health inequalities, with a higher burden seen among women, in high SDI countries, and regions like Asia.

The rising incidence of joint disorders is a key driver of the viscosupplementation market. Degenerative conditions are becoming more common due to aging populations and sedentary lifestyles. This is leading to greater demand for non-surgical treatment approaches that provide symptom relief. Viscosupplementation addresses this by improving joint lubrication and mobility. Healthcare systems are recognizing the cost-effectiveness of delaying surgical intervention. In November 2024, an article in Osteoarthritis and Cartilage highlighted that osteoarthritis affected 7.6% of the global population in 2020, with prevalence increasing by 132.2% over the past 30 years. Moreover, it is noted that early-onset OA cases, occurring before age 55, accounted for over half of new diagnoses and 26.1% of total YLDs.

Preference for minimally invasive treatment options is contributing to market expansion. Patients and providers are increasingly opting for procedures that offer reduced recovery time and fewer complications. Viscosupplementation aligns with these needs, supporting its adoption in routine clinical practice. Ongoing developments in formulation are also influencing uptake. Single and multiple-injection regimens are now available to accommodate different patient profiles. In April 2024, a study published in Cureus analyzed arthritis trends among U.S. adults using BRFSS data from 2019 to 2022. The findings underscored rising prevalence and disparities by demographics and health status. These insights support growing adoption of minimally invasive surgeries (MIS) for arthritis, aimed at reducing pain, complications, and recovery time.

Growing awareness among healthcare providers and structured reimbursement policies are further supporting market growth. Continued clinical validation has led to broader acceptance of viscosupplementation in standard care protocols. This is encouraging its use at earlier stages of joint degeneration. Market players are responding with expanded product offerings to meet rising clinical demand. Regional regulatory support has facilitated product availability across key markets. In January 2024, Seikagaku Corporation announced collaborations with Anika Therapeutics and two other manufacturers to enhance multi-injection viscosupplementation products using novel cross-linked hyaluronic acid technologies.

Global Viscosupplementation Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viscosupplementation market report based on product, end use, and region:

• Product Outlook (Revenue in USD Billion, 2021 - 2033)
• Single Injection
• Three Injection
• Five Injection
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Orthopedic Clinics/ASCs
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o France
o Germany
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Viscosupplementation Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of osteoarthritis among aging populations
3.2.1.2. Rising demand for non-surgical pain management options in orthopedics
3.2.1.3. Advancements in hyaluronic acid formulations improving product efficacy
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment limiting access in low- and middle-income countries
3.2.2.2. Limited long-term effectiveness leading to physician skepticism and guideline restrictions
3.3. Viscosupplementation: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTLE Analysis
Chapter 4. Viscosupplementation Market Segment Analysis, By Product, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Product Market Share Analysis, 2024 & 2033
4.3. Segment Dashboard
4.4. Global viscosupplementation market, by product, 2021 to 2033
4.5. Single injection
4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. Three injection
4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
4.7. Five injection
4.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Viscosupplementation Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Segment Dashboard
5.3. Global viscosupplementation market, by End Use, 2021 to 2033
5.4. Hospitals
5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Orthopedic Clinic/ASCs
5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Viscosupplementation Market Segment Analysis, By Region, 2021 - 2033 (USD Million)
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Regional Market Snapshot
6.4. Viscosupplementation Market Share by Region, 2024 & 2033:
6.5. North America
6.5.1. North America viscosupplementation market, 2021 - 2033 (USD Million)
6.5.2. U.S.
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Scenario
6.5.2.4. U.S. viscosupplementation market, 2021 - 2033 (USD Million)
6.5.3. Canada
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Scenario
6.5.3.4. Canada viscosupplementation market, 2021 - 2033 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Scenario
6.5.4.4. Mexico viscosupplementation market, 2021 - 2033 (USD Million)
6.6. Europe
6.6.1. Europe viscosupplementation market, 2021 - 2033 (USD Million)
6.6.2. UK
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Scenario
6.6.2.4. UK viscosupplementation market, 2021 - 2033 (USD Million)
6.6.3. Germany
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Scenario
6.6.3.4. Germany viscosupplementation market, 2021 - 2033 (USD Million)
6.6.4. France
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Scenario
6.6.4.4. France viscosupplementation market, 2021 - 2033 (USD Million)
6.6.5. Italy
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Scenario
6.6.5.4. Italy viscosupplementation market, 2021 - 2033 (USD Million)
6.6.6. Spain
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Scenario
6.6.6.4. Spain viscosupplementation market, 2021 - 2033 (USD Million)
6.6.7. Norway
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Scenario
6.6.7.4. Norway viscosupplementation market, 2021 - 2033 (USD Million)
6.6.8. Sweden
6.6.8.1. Key Country Dynamics
6.6.8.2. Regulatory Framework
6.6.8.3. Competitive Scenario
6.6.8.4. Sweden viscosupplementation market, 2021 - 2033 (USD Million)
6.6.9. Denmark
6.6.9.1. Key Country Dynamics
6.6.9.2. Regulatory Framework
6.6.9.3. Competitive Scenario
6.6.9.4. Denmark viscosupplementation market, 2021 - 2033 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key Country Dynamics
6.7.1.2. Regulatory Framework
6.7.1.3. Competitive Scenario
6.7.1.4. Japan viscosupplementation market, 2021 - 2033 (USD Million)
6.7.2. China
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Scenario
6.7.2.4. China viscosupplementation market, 2021 - 2033 (USD Million)
6.7.3. India
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Scenario
6.7.3.4. India viscosupplementation market, 2021 - 2033 (USD Million)
6.7.4. Australia
6.7.4.1. Key Country Dynamics
6.7.4.2. Regulatory Framework
6.7.4.3. Competitive Scenario
6.7.4.4. Australia viscosupplementation market, 2021 - 2033 (USD Million)
6.7.5. South Korea
6.7.5.1. Key Country Dynamics
6.7.5.2. Regulatory Framework
6.7.5.3. Competitive Scenario
6.7.5.4. South Korea viscosupplementation market, 2021 - 2033 (USD Million)
6.7.6. Thailand
6.7.6.1. Key Country Dynamics
6.7.6.2. Regulatory Framework
6.7.6.3. Competitive Scenario
6.7.6.4. Thailand viscosupplementation market, 2021 - 2033 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key Country Dynamics
6.8.1.2. Regulatory Framework
6.8.1.3. Competitive Scenario
6.8.1.4. Brazil viscosupplementation market, 2021 - 2033 (USD Million)
6.8.2. Argentina
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Scenario
6.8.2.4. Argentina viscosupplementation market, 2021 - 2033 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key Country Dynamics
6.9.1.2. Regulatory Framework
6.9.1.3. Competitive Scenario
6.9.1.4. South Africa viscosupplementation market, 2021 - 2033 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key Country Dynamics
6.9.2.2. Regulatory Framework
6.9.2.3. Competitive Scenario
6.9.2.4. Saudi Arabia viscosupplementation market, 2021 - 2033 (USD Million)
6.9.3. UAE
6.9.3.1. Key Country Dynamics
6.9.3.2. Regulatory Framework
6.9.3.3. Competitive Scenario
6.9.3.4. UAE viscosupplementation market, 2021 - 2033 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key Country Dynamics
6.9.4.2. Regulatory Framework
6.9.4.3. Competitive Scenario
6.9.4.4. Kuwait viscosupplementation market, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company Categorization
7.3. Company Profiles
7.4. Heatmap Analysis, 2024
7.5. Company Profile
7.5.1. DePuy Synthes
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic initiatives
7.5.2. Fidia Farmaceutici S.p.A
7.5.2.1. Company Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic initiatives
7.5.3. Sanofi
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic initiatives
7.5.4. Anika Therapeutics, Inc.
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic initiatives
7.5.5. SEIKAGAKU CORPORATION
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic initiatives
7.5.6. Zimmer Biomet
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic initiatives
7.5.7. Smith & Nephew PLC
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Ferring Pharmaceutical B.V.
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Lifecore Biomedical, LLC (Landec)
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic initiatives
7.5.10. LG Life Sciences Ltd.
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic initiatives
7.5.11. F. Hoffmann-La Roche Ltd.
7.5.11.1. Company Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic initiatives